Literature DB >> 1907542

Role of gamma interferon in Toxoplasma gondii infection.

C S Subauste1, J S Remington.   

Abstract

Toxoplasma gondii has emerged as an important pathogen in the ever increasing numbers of patients with disorders of the immune system. Better understanding of the mechanisms of resistance of the host against this protozoan is important for development of safe, effective alternative treatment regimens for toxoplasmosis. Gamma interferon is the cytokine that plays a central role in protection against Toxoplasma gondii. The purpose of this review is to highlight the current knowledge of the role of gamma interferon in Toxoplasma gondii infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1907542     DOI: 10.1007/bf01964408

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  80 in total

1.  Role of TNF and IL-1 in infections with Toxoplasma gondii.

Authors:  H R Chang; G E Grau; J C Pechère
Journal:  Immunology       Date:  1990-01       Impact factor: 7.397

2.  Spleen and lymph node cell populations, in vitro cell proliferation and interferon-gamma production during the primary immune response to Toxoplasma gondii.

Authors:  T C Jones; S Alkan; P Erb
Journal:  Parasite Immunol       Date:  1986-11       Impact factor: 2.280

3.  Dual regulation of resistance against Toxoplasma gondii infection by Lyt-2+ and Lyt-1+, L3T4+ T cells in mice.

Authors:  Y Suzuki; J S Remington
Journal:  J Immunol       Date:  1988-06-01       Impact factor: 5.422

4.  Deficiency of immune interferon production by leukocytes of normal newborns.

Authors:  Y J Bryson; H S Winter; S E Gard; T J Fischer; E R Stiehm
Journal:  Cell Immunol       Date:  1980-09-15       Impact factor: 4.868

5.  Treatment of toxoplasmic encephalitis in mice with recombinant gamma interferon.

Authors:  Y Suzuki; F K Conley; J S Remington
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

6.  Activation of tissue macrophages from AIDS patients: in vitro response of AIDS alveolar macrophages to lymphokines and interferon-gamma.

Authors:  H W Murray; R A Gellene; D M Libby; C D Rothermel; B Y Rubin
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

7.  Toxoplasma gondii infection of the central nervous system. Use of the peroxidase-antiperoxidase method to demonstrate toxoplasma in formalin fixed, paraffin embedded tissue sections.

Authors:  F K Conley; K A Jenkins; J S Remington
Journal:  Hum Pathol       Date:  1981-08       Impact factor: 3.466

8.  Strain differences of interferon-generating capacity and resistance in toxoplasma-infected mice.

Authors:  T Shirahata; A Mori; H Ishikawa; H Goto
Journal:  Microbiol Immunol       Date:  1986       Impact factor: 1.955

9.  Inhibition of multiplication of Toxoplasma gondii by human monocytes exposed to T-lymphocyte products.

Authors:  J S Borges; W D Johnson
Journal:  J Exp Med       Date:  1975-02-01       Impact factor: 14.307

10.  Activation of human macrophages. Comparison of other cytokines with interferon-gamma.

Authors:  C F Nathan; T J Prendergast; M E Wiebe; E R Stanley; E Platzer; H G Remold; K Welte; B Y Rubin; H W Murray
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307

View more
  10 in total

Review 1.  The development and biology of bradyzoites of Toxoplasma gondii.

Authors:  L M Weiss; K Kim
Journal:  Front Biosci       Date:  2000-04-01

2.  Changes in cytokine levels during reactivation of Toxoplasma gondii infection in lungs.

Authors:  G A Filice; C R Clabots; P E Riciputi; O Goñi-Laguardia; C Pomeroy
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  Induction of heat shock protein closely correlates with protection against Toxoplasma gondii infection.

Authors:  H Nagasawa; M Oka; K Maeda; C Jian-Guo; H Hisaeda; Y Ito; R A Good; K Himeno
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

4.  Impairment of host defense against disseminated candidiasis in mice overexpressing GATA-3.

Authors:  Norihiro Haraguchi; Yukio Ishii; Yuko Morishima; Keigyou Yoh; Yosuke Matsuno; Norihiro Kikuchi; Tohru Sakamoto; Satoru Takahashi; Nobuyuki Hizawa
Journal:  Infect Immun       Date:  2010-03-15       Impact factor: 3.441

5.  Reduced replication of Toxoplasma gondii is necessary for induction of bradyzoite-specific antigens: a possible role for nitric oxide in triggering stage conversion.

Authors:  W Bohne; J Heesemann; U Gross
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

6.  Induction of bradyzoite-specific Toxoplasma gondii antigens in gamma interferon-treated mouse macrophages.

Authors:  W Bohne; J Heesemann; U Gross
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

7.  Evaluation of the adjuvant effect of pidotimod on the immune protection induced by UV-attenuated Toxoplasma gondii in mouse models.

Authors:  Ying Zhao; Bo Huang; Shiguang Huang; Huanqin Zheng; Yun-quan Li; Zhao-rong Lun; Jilong Shen; Yong Wang; Lloyd H Kasper; Fangli Lu
Journal:  Parasitol Res       Date:  2013-06-20       Impact factor: 2.289

8.  Disruption of the expression of a non-coding RNA significantly impairs cellular differentiation in Toxoplasma gondii.

Authors:  Veerupaxagouda Patil; Pamela J Lescault; Dario Lirussi; Ann B Thompson; Mariana Matrajt
Journal:  Int J Mol Sci       Date:  2012-12-28       Impact factor: 5.923

9.  ATF6beta is a host cellular target of the Toxoplasma gondii virulence factor ROP18.

Authors:  Masahiro Yamamoto; Ji Su Ma; Christina Mueller; Naganori Kamiyama; Hiroyuki Saiga; Emi Kubo; Taishi Kimura; Toru Okamoto; Megumi Okuyama; Hisako Kayama; Kisaburo Nagamune; Seiji Takashima; Yoshiharu Matsuura; Dominique Soldati-Favre; Kiyoshi Takeda
Journal:  J Exp Med       Date:  2011-06-13       Impact factor: 14.307

10.  Interferon consensus sequence binding protein-deficient mice display impaired resistance to intracellular infection due to a primary defect in interleukin 12 p40 induction.

Authors:  T Scharton-Kersten; C Contursi; A Masumi; A Sher; K Ozato
Journal:  J Exp Med       Date:  1997-11-03       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.